Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease.

Kapogiannis D, Boxer A, Schwartz JB, Abner EL, Biragyn A, Masharani U, Frassetto L, Petersen RC, Miller BL, Goetzl EJ.

FASEB J. 2015 Feb;29(2):589-96. doi: 10.1096/fj.14-262048. Epub 2014 Oct 23.

2.

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study.

Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ.

Alzheimers Dement. 2015 Jun;11(6):600-7.e1. doi: 10.1016/j.jalz.2014.06.008. Epub 2014 Aug 15.

3.

Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer's disease.

Mullins RJ, Mustapic M, Goetzl EJ, Kapogiannis D.

Hum Brain Mapp. 2017 Apr;38(4):1933-1940. doi: 10.1002/hbm.23494. Epub 2017 Jan 20.

4.

Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease.

Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, Kapogiannis D.

Neurology. 2015 Jul 7;85(1):40-7. doi: 10.1212/WNL.0000000000001702. Epub 2015 Jun 10.

5.

Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease.

Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, Jicha GA, Karydas AM, Boxer A, Miller BL.

FASEB J. 2016 Dec;30(12):4141-4148. Epub 2016 Sep 6.

6.

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG.

J Clin Invest. 2012 Apr;122(4):1339-53. doi: 10.1172/JCI57256.

7.

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE.

J Clin Invest. 2012 Apr;122(4):1316-38. doi: 10.1172/JCI59903.

8.

Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease.

Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach IV, Goetzl L, Schwartz JB, Miller BL.

FASEB J. 2016 Nov;30(11):3853-3859. Epub 2016 Aug 10.

9.

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling.

Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C.

Neurobiol Aging. 2010 Feb;31(2):224-43. doi: 10.1016/j.neurobiolaging.2008.04.002.

PMID:
18479783
10.

Deficient neurotrophic factors of CSPG4-type neural cell exosomes in Alzheimer disease.

Goetzl EJ, Nogueras-Ortiz C, Mustapic M, Mullins RJ, Abner EL, Schwartz JB, Kapogiannis D.

FASEB J. 2019 Jan;33(1):231-238. doi: 10.1096/fj.201801001. Epub 2018 Jun 20.

PMID:
29924942
12.

C1qTNF-related protein 1 improve insulin resistance by reducing phosphorylation of serine 1101 in insulin receptor substrate 1.

Xin Y, Zhang D, Fu Y, Wang C, Li Q, Tian C, Zhang S, Lyu X.

Endocr J. 2017 Aug 30;64(8):787-796. doi: 10.1507/endocrj.EJ17-0128. Epub 2017 Jul 1.

13.

Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus.

Moroz N, Tong M, Longato L, Xu H, de la Monte SM.

J Alzheimers Dis. 2008 Sep;15(1):29-44.

PMID:
18780965
14.

18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.

Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, Haense C, Richardson AM, Gerhard A, Anton-Rodriguez JM, Snowden JS, Neary D, Pontecorvo MJ, Herholz K.

J Nucl Med. 2015 Mar;56(3):386-91. doi: 10.2967/jnumed.114.147454. Epub 2015 Feb 5.

15.

Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.

Sorensen KC, Simonsen AH, Holmetoft UB, Hasselbalch SG, Heegaard NH.

J Alzheimers Dis. 2013;37(2):379-87. doi: 10.3233/JAD-122410. Erratum in: J Alzheimers Dis. 2014;40(4):1063.

PMID:
23948879
16.
17.

Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation.

Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G, Olefsky JM.

J Clin Endocrinol Metab. 2002 Jan;87(1):226-34.

PMID:
11788651
18.

TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys.

Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF, Sathler LB, Brito-Moreira J, Amaral OB, Silva CA, Freitas-Correa L, Espírito-Santo S, Campello-Costa P, Houzel JC, Klein WL, Holscher C, Carvalheira JB, Silva AM, Velloso LA, Munoz DP, Ferreira ST, De Felice FG.

Cell Metab. 2013 Dec 3;18(6):831-43. doi: 10.1016/j.cmet.2013.11.002.

19.

Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.

Diamandis EP, Scorilas A, Kishi T, Blennow K, Luo LY, Soosaipillai A, Rademaker AW, Sjogren M.

Clin Biochem. 2004 Mar;37(3):230-7.

PMID:
14972646

Supplemental Content

Support Center